25B-NBF

Source: Wikipedia, the free encyclopedia.
25B-NBF
Clinical data
ATC code
  • (HCl): none
Legal status
Legal status
Identifiers
  • 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-fluorobenzyl)ethanamine
JSmol)
  • (HCl): COC1=CC(CCNCC2=CC=CC=C2F)=C(OC)C=C1Br
  • (HCl): InChI=1S/C17H19BrFNO2.ClH/c1-21-16-10-14(18)17(22-2)9-12(16)7-8-20-11-13-5-3-4-6-15(13)19;/h3-6,9-10,20H,7-8,11H2,1-2H3;1H

25B-NBF (2C-B-NBF, NBF-2C-B) is a derivative of the phenethylamine hallucinogen 2C-B, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1][2]

Legality

Sweden

The Riksdag added 25B-NBF to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of January 26, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:35 listed as 25B-NBF, and 2-(4-bromo-2,5-dimetoxifenyl)-N-(2-fluorobensyl)etanamin.[3]

United Kingdom

This substance is a

Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[4]

Analogues and derivatives

References